Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 09/26 10:00:17 pm
55.48 USD   -1.77%
09/26BRISTOL-MYERS S : Attractive price levels
09/22 BRISTOL MYERS S : to Take Part in Leerink Partners Immuno-Oncology R..
09/20 BRISTOL MYERS S : Awards First “Golden Tickets” for LabC..
News SummaryMost relevantAll newsSector news 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
09/22 BRISTOL MYERS SQUIBB : to Take Part in Leerink Partners Immuno-Oncology Roundtab..
09/22 BRISTOL MYERS SQUIBB : FDAnews Announces -- Future-Proofing Your Clinical Trial ..
09/20 BRISTOL MYERS SQUIBB : Awards First “Golden Tickets” for LabCentral ..
09/20 BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol-Myers Squibb&..
09/20 BRISTOL MYERS SQUIBB : Nippon Life Insurance Co Lowers stake in Bristol-Myers Sq..
09/15 BRISTOL MYERS SQUIBB : An Application for the Trademark "TOGEVDO" Has Been Filed..
09/15 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Further Understanding o..
09/15 BRISTOL MYERS SQUIBB : Reports from Bristol-Myers Squibb Advance Knowledge in Me..
09/15 FINDINGS FROM BRISTOL-MYERS SQUIBB P : Defining molecular...
09/15 BRISTOL MYERS SQUIBB : to Announce Results for Third Quarter 2016 on October 27
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 BUY ABBVIE INCORPORATED : Its Frustration Is Your Long-Term Gain
09/22 Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisiti..
09/21 Gilead nixes clinical development of GS-5745 for ulcerative colitis
09/21 ALLERGAN : Examining The Premiums Paid
09/20 Bristol-Myers' marketing application for new use of Opdivo accepted for revie..
Financials ($)
Sales 2016 18 872 M
EBIT 2016 4 999 M
Net income 2016 4 369 M
Debt 2016 1 166 M
Yield 2016 2,79%
P/E ratio 2016 21,45
P/E ratio 2017 18,56
EV / Sales 2016 4,97x
EV / Sales 2017 4,52x
Capitalization 92 699 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 67,4 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results